A Study to Assess Topoisomerase II Alpha (TOPO2A) as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Latest Information Update: 08 Dec 2024
Price :
$35 *
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Biomarker; Therapeutic Use
- 04 Dec 2024 Planned primary completion date changed from 1 Dec 2021 to 15 Oct 2026.
- 04 Dec 2024 Planned End Date changed from 1 Oct 2024 to 1 Oct 2027.
- 01 Jul 2024 Planned End Date changed from 1 May 2024 to 1 Oct 2024.